Targeted therapy duo takes aim at hard-to-treat blood cancer
NCT ID NCT05038592
First seen Jan 09, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This study tests a combination of two drugs—tagraxofusp and decitabine—for people with chronic myelomonocytic leukemia or related high-risk blood disorders. Tagraxofusp delivers a toxin directly to cancer cells, while decitabine is a chemotherapy that stops cancer growth. The goal is to find the best dose and see how well the combo controls the disease. About 64 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.